down arrow

Larimar Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US5171251003
USD
3.68
0.56 (17.95%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

3.363.75

52 Week

1.616.91
Valuation
Technical
Day's Volume

CASH

1.01 M

Shareholding (Mar 2025)

FII

3.78%

Held by 46 FIIs

DII

40.78%

Held by 22 DIIs

Promoter

40.86%

How big is Larimar Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Larimar Therapeutics, Inc. has a market capitalization of 172.24 million, with net sales of 0.00 million and a net profit of -95.23 million over the latest four quarters. The company reported shareholder's funds of 171.81 million and total assets of 200.93 million as of Dec 24.

Market Cap: As of Jun 18, Larimar Therapeutics, Inc. has a market capitalization of 172.24 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Larimar Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -95.23 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 171.81 million and total assets of 200.93 million.

Read More

What does Larimar Therapeutics, Inc. do?

22-Jun-2025

Larimar Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases using cell penetrating peptide technology. It has a market cap of $172.24 million and reported a net profit loss of $29 million as of March 2025.

Overview: <BR>Larimar Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for complex rare diseases using its cell penetrating peptide technology platform, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -29 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 172.24 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.08 <BR>Return on Equity: -66.01% <BR>Price to Book: 1.19<BR><BR>Contact Details: <BR>Address: THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD PA: 19004 <BR>Tel: 1 617 6224003 <BR>Fax: 1 302 6555049 <BR>Website: https://larimartx.com/

Read More

Who are in the management team of Larimar Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Larimar Therapeutics, Inc. includes Mr. Joseph Truitt (Chairman), Dr. Carole Ben-Maimon (President and CEO), and Board members Mr. Thomas Hamilton, Mr. Jonathan Leff, Dr. Thomas Daniel, and Mr. Frank Thomas.

As of March 2022, the management team of Larimar Therapeutics, Inc. includes Mr. Joseph Truitt as the Chairman of the Board, Dr. Carole Ben-Maimon serving as the President, Chief Executive Officer, and Director, along with Mr. Thomas Hamilton, Mr. Jonathan Leff, Dr. Thomas Daniel, and Mr. Frank Thomas, who are all members of the Board of Directors in various capacities.

Read More

Is Larimar Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 29, 2025, Larimar Therapeutics, Inc. shows a mildly bullish trend with daily moving averages and weekly indicators supporting this outlook, despite mixed signals from monthly metrics and a one-year return of -37.52% compared to the S&P 500's 17.14%.

As of 29 August 2025, the technical trend for Larimar Therapeutics, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD and Bollinger Bands indicate a bullish stance, while the monthly MACD and KST are bearish, suggesting mixed signals across different time frames. The daily moving averages are bullish, supporting the overall mildly bullish outlook. The stock has outperformed the S&P 500 over the past week and month, returning 2.64% and 9.74% respectively, but has underperformed over the longer term, with a 1-year return of -37.52% compared to the S&P 500's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 336 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.15

stock-summary
Return on Equity

-83.26%

stock-summary
Price to Book

2.81

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-26 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-6.6%
0%
-6.6%
6 Months
52.7%
0%
52.7%
1 Year
-39.37%
0%
-39.37%
2 Years
3.95%
0%
3.95%
3 Years
16.46%
0%
16.46%
4 Years
-61.63%
0%
-61.63%
5 Years
-84.97%
0%
-84.97%

Larimar Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Larimar Therapeutics, Inc. technically bullish or bearish?

As of 29 August 2025, the technical trend for Larimar Therapeutics, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD and Bollinger Bands indicate a bullish stance, while the monthly MACD and KST are bearish, suggesting mixed signals across different time frames. The daily moving averages are bullish, supporting the overall mildly bullish outlook. The stock has outperformed the S&P 500 over the past week and month, returning 2.64% and 9.74% respectively, but has underperformed over the longer term, with a 1-year return of -37.52% compared to the S&P 500's 17.14%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-211.27%
EBIT to Interest (avg)
-51.78
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.08
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.19
EV to EBIT
-0.14
EV to EBITDA
-0.14
EV to Capital Employed
-1.25
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-66.01%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bullish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 30 Schemes (14.59%)

Foreign Institutions

Held by 46 Foreign Institutions (3.78%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -21.30% vs -157.14% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-27.70",
          "val2": "-24.50",
          "chgp": "-13.06%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-26.20",
          "val2": "-21.60",
          "chgp": "-21.30%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -118.43% vs -4.24% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-90.60",
          "val2": "-41.40",
          "chgp": "-118.84%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-80.60",
          "val2": "-36.90",
          "chgp": "-118.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-27.70
-24.50
-13.06%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-26.20
-21.60
-21.30%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -21.30% vs -157.14% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-90.60
-41.40
-118.84%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-80.60
-36.90
-118.43%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -118.43% vs -4.24% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Larimar Therapeutics, Inc. stock-summary
stock-summary
Larimar Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Larimar Therapeutics Inc., formerly Zafgen, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for complex rare diseases using its cell penetrating peptide technology platform. The Company’s protein replacement therapy platform provides disease-modifying therapies that intends to deliver missing proteins inside the machinery of cells to treat devastating rare diseases that have no treatments available. The Company’s lead product candidate, CTI-1601, is a recombinant fusion protein intended to deliver human frataxin (FXN) into the mitochondria of patients with Friedreich’s ataxia (FA). CTI-1601 is in Phase I clinical program. The Company intends to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Company Coordinates stock-summary
Company Details
THREE BALA PLAZA EAST. SUITE 506 , BALA CYNWYD PA : 19004
stock-summary
Tel: 1 617 6224003
stock-summary
https://larimartx.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."